This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visist to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy
Versameb Chief Executive Officer to Present at LSX Inv€$tival Showcase Conference
news versamebPRESS RELEASE | Basel, Switzerland, November 10, 2022
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s proprietary mRNA engineering technology platform, VERSagile, at the LSX Inv€$tival Showcase Conference taking place on 14 November 2022 at Old Billingsgate in London, UK.
Versameb to present at the BIO Asia-Taiwan Conference
news versamebPRESS RELEASE | Basel, Switzerland, July 22, 2022
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s mRNA engineering technology platform VERSagile and lead therapeutic candidate VMB-100 at the BIO Asia-Taiwan Conference, taking place on 27-31 July 2022 in Taiwan.
Versameb to Present during World Continence Week 2022
news versamebPRESS RELEASE | Basel, Switzerland, June 20, 2022
Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, is pleased to announce that Chief Executive Officer Klaas Zuideveld and Clinical Advisor Prof. Roger Dmochowski will be presenting Versameb’s lead therapeutic candidate, VMB-100, for the treatment of Stress Urinary Incontinence (SUI) at World Continence Week (WCW) 20-26 June 2022. WCW is an annual initiative fully endorsed by the European Association of Urology (EAU) and the International Continence Society (ICS) set up by the World Federation of Incontinence and Pelvic Problems (WFIPP) to raise awareness of bladder & bowel issues, chronic pelvic pain and other debilitating conditions which impact the lives of millions of patients worldwide.
Versameb to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
news versamebPRESS RELEASE | Basel, Switzerland, April 5, 2022
Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces it will present a poster entitled ‘Design of combinatory RNA molecules to simultaneously activate tumor immunity and target several signaling pathways in solid tumors’ on the 11th of April at the American Association of Cancer Research (AACR) Annual Meeting, taking place in New Orleans, USA on the 8 – 13 April 2022.
Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress
news versamebPRESS RELEASE | Basel, Switzerland, March 10, 2022
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the RNA Leaders World Congress, taking place on the 16-17th March 2022 in Basel, Switzerland, where Chief Executive Officer Klaas Zuideveld will be presenting data on the Company’s mRNA engineering technology and its lead therapeutic candidate, VMB-100.